Acute lymphoblastic leukaemia (ALL) in infancy, defined as ≤1 year of age at diagnosis, is rare with an incidence of 1.8 cases per 100,000 [1]. KMT2A-gene rearrangements are present in up to 80% of infants with ALL and are associated with a poor prognosis. Historically, collaborative group treatment protocols have focused on intensification of conventional chemotherapy, which can include allogeneic haematopoietic stem cell transplant (HSCT) for high-risk infants, however outcomes for KMT2Arearranged infant ALL have remained poor due to high relapse rates and treatment-related mortality [2, 3]. Given the rarity of the patient population and low survival rates, there is limited data regarding long-term outcomes in survivors of infant ALL in the context of receiving intensive therapy to achieve a cure. We conducted a multi-centre retrospective analysis of all infants diagnosed with ALL in Australia and New Zealand from 1 January 1992 to 31 December 2011 (Human Research Ethics Approval RGS0000001383). Patients were identified from the cancer registry of every paediatric cancer centre in Australia and New Zealand and standardised data were captured for each patient until 28 February 2021, including demographics, disease characteristics, treatment, outcome, a systematic capture of late effects based on the Children's Oncology Group long-term followup guidelines (version 5.0) and date of last follow-up. Event-free survival (EFS) was defined as the time from ALL diagnosis to treatment failure or relapse, all-cause mortality, or second malignancy. Overall survival (OS) was defined as the time from diagnosis to all-cause mortality. Time was censored at the last follow-up if no events were recorded. All analyses were performed using R (version 4.2.2). Over the 20-year period, 119 infants were diagnosed with ALL in Australia and New Zealand. Treatment was administered according to US or European-based infant-specific collaborative group protocols available at the time of diagnosis. Fiveyear OS was 60.5% (SE 4.5) and 5-year EFS was 47.1% (SE 4.7) (Fig. 1; Supplementary Fig. 1). EFS and OS were adversely influenced by the presence of a KMT2A-rearrangement, age <6 months, central nervous system (CNS) involvement, high presenting white blood cell count and CD10-negative immunophenotype, with male sex also an adverse prognostic factor for EFS on univariate analysis (Table 1; Supplementary Fig. 2). Cox regression analysis, with EFS as an endpoint, identified presence of a KMT2A-rearrangement, age <6 months and male